Literature DB >> 16458684

Ocular surface restoration using non-surgical transplantation of tissue-cultured human amniotic epithelial cells.

Dipak N Parmar1, Hassan Alizadeh, Shady T Awwad, Haochuan Li, Sudha Neelam, R Wayne Bowman, H Dwight Cavanagh, James P McCulley.   

Abstract

PURPOSE: To assess the effect of tissue-cultured human amniotic epithelial cells (AECs) in restoring the ocular surface, transplanted using a collagen shield seeded with AECs supported by a soft contact lens.
DESIGN: Prospective interventional single-institutional case series with crossover controls.
METHODS: Three eyes in three patients were identified with persistent corneal epithelial defects (PEDs) refractory to medical therapy. Two cases were secondary to neurotrophic keratopathy, while one case was attributable to longstanding alkali injury. AECs were isolated from serologically screened donor human placenta, seeded onto collagen corneal shields, and incubated in tissue culture medium for 7 days. These collagen shields were placed over the PED and supported by an overlying soft contact lens. The collagen shields dissolved by 72 hours, and the contact lenses were removed after this time. This cycle was repeated every week until healing was achieved. As a crossover control, collagen shields without AECs were placed in the same eye 1 week before placing collagen shields containing AECs. The PED was assessed by vital staining and slit-lamp color photography.
RESULTS: The PEDs had a mean duration of 4 months and involved 20% to 37% of the corneal surface area, one case secondary to longstanding alkali injury and two cases attributable to neurotrophic keratopathy. No change in PED size was observed in those control eyes receiving collagen shields without AECs. Complete resolution of the PED was seen after two cycles of AEC-seeded collagen shield in one case, and four cycles in two cases, from 7 to 12 weeks following treatment in all patients. No loss of visual acuity was seen and clinical improvement was maintained in all cases, with a mean follow-up of 6.3 months.
CONCLUSIONS: Nonsurgical transplantation of tissue-cultured AECs on a collagen shield provides a promising approach to restoring the ocular surface in cases of PED.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458684     DOI: 10.1016/j.ajo.2005.09.008

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  In vitro tissue engineering of lamellar cornea using human amniotic epithelial cells and rabbit cornea stroma.

Authors:  Xiao-Yong Liu; Jian Chen; Qing Zhou; Jing Wu; Xiao-Ling Zhang; Li Wang; Xiao-Yan Qin
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

2.  Efficacy of self-retained cryopreserved amniotic membrane for treatment of neuropathic corneal pain.

Authors:  Melina I Morkin; Pedram Hamrah
Journal:  Ocul Surf       Date:  2017-10-13       Impact factor: 5.033

3.  Regulating Early Biological Events in Human Amniotic Epithelial Stem Cells Using Natural Bioactive Compounds: Extendable Multidirectional Research Avenues.

Authors:  Farhana Ferdousi; Hiroko Isoda
Journal:  Front Cell Dev Biol       Date:  2022-04-01

4.  Human amniotic epithelial cell-derived extracellular vesicles provide an extracellular matrix-based microenvironment for corneal injury repair.

Authors:  Shuqin Hu; Zhe Wang; Caixia Jin; Qizhen Chen; Yuchen Fang; Jiahui Jin; Jie Chen; Lixia Lu; Haibin Tian; Jingying Xu; Furong Gao; Juan Wang; Jieping Zhang; Hong-Ping Cui; Guo-Tong Xu; Qingjian Ou
Journal:  J Tissue Eng       Date:  2022-09-06       Impact factor: 7.940

5.  Amniotic membrane-derived stem cells help repair osteochondral defect in a weight-bearing area in rabbits.

Authors:  Zhijin Zhang; Linru Zeng; Jun Yang; Lin Guo; Qiao Hou; Fangbing Zhu
Journal:  Exp Ther Med       Date:  2017-05-23       Impact factor: 2.447

Review 6.  Human Amniotic Epithelial Stem Cells: A Promising Seed Cell for Clinical Applications.

Authors:  Chen Qiu; Zhen Ge; Wenyu Cui; Luyang Yu; Jinying Li
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.